Clinical Trial Search

Primary: The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48), ANCOVA Model…

Primary: Change From 6 Months to Baseline in Visual Analogue Scale (VAS) Pain After 15 Minutes of Sitting — -28.1 mm

Primary: Procedural Time — 577; 206 seconds

Primary: Panic Disorder Severity Scale (PDSS) — 9.13 units on a scale

Primary: Length of Hospital Stay — 3.5; 2.6 days

Primary: Frequency of Subjects With Moderate/Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis. — 53; 99 Number of…

Primary: Summary of Participants With Treatment Emergent Adverse Events (TEAEs) — 18; 14; 11; 0 Participants

Primary: Improvement as Measured by Change in Clinical Global Impression of Severity (CGI-S) Rating From Baseline — 17; 10 Participants

Primary: Percent Abstinent From Tobacco at Week 12 (7 Day Point Prevalence) — 31; 17 percentage of randomized — p=0.04

Primary: Investigator-assessed Progression-free Survival (PFS) — 12.3; 17.9 months — p=0.0021

Primary: Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria — 10; 1 participants

Primary: Summary of Sensitivity of the Blinded Visual PET Image Interpretations Without Anatomic Images. — 94; 92; 90; 94 Percentage (True Positive)

Primary: The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48) — 508.2; 329.8…

Primary: Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase…

Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -10.77; -12.96; -14.41 scores on a scale — p=0.058